Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime. | May 1, 2023
Operator: Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call. It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations. Thank you.